TB-500

“TB-500” is a marketplace term often associated with thymosin beta-4 or a related fragment. Exact sequence and molecular identity must be confirmed before scientific literature can be assigned to the product.

Full-length thymosin beta-4 binds G-actin and has been studied in cytoskeletal organization, cell migration, angiogenesis, and wound models. A fragment may have different properties.

Preclinical and some human research exists for defined thymosin beta-4 products; evidence for undefined TB-500 material is unestablished.

Identity-dependent, Evidence cannot be assigned

Literature on full-length thymosin beta-4 cannot substantiate a fragment or mislabeled material. Sequence, mass, purity, and content are mandatory.

Potential concerns include angiogenic or proliferative effects, immunogenicity, contamination, and unknown fragment-specific toxicity.

No FDA-approved TB-500 drug product; identity and intended use are critical.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• TB-500 / Thymosin Beta-4-Related Material, 5 mgLyophilized
• TB-500 / Thymosin Beta-4-Related Material, 10 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.